ATXN2 and autosomal dominant cerebellar ataxia: In the case of MK801, a noncompetitive antagonist of the NMDA receptor, and NBQX, an AMPA/kainate antagonist, our results showed that the compounds can only improve some of the SCA-relevant phenotypes in the SCA2 and SCA3-iPSC-derived neurons.